1.Anterior Interbody Fusion and Posterior Instrumentation for Degenerative Lumbar Spondylolisthesis.
Dae Hyun PAEK ; Ju Hae JAHNG ; Han CHANG ; Won Jong BAHK ; Seung Pyo EUN ; Jong Min SOHN ; Gwan Soo LIM
The Journal of the Korean Orthopaedic Association 1998;33(2):359-366
Degenerative lumbar spondylolisthesis requires fusion of the involved segments and decompression laminectomy because it is mechanically unstahle and usually associated with stenosis of the spinal canal. Transabdominal retroperitoneal approach through small longitudinal pararectal skin incision provides easy and safe access to L3-4 and L4-5 disc spaces with less bleeding. We thought that anterior interbody fusion enable us to restore the disc space and to reduce partially the listhesis with less hleeding and less harvest of graft hone compared to posterolateral fusion, and also without the risk of neural or dural damage which could he occurred in posterior lumbar interbody fusion 4.15.16.17). Thus, authors performed the same-day anterior and posterior spinal surgery (APSS) in 28 patients (30 disc spaces) from 1992 to 1996 and analyzed the clinical and radiological results. The most common site of involvement was L4-5 level (82.1%). The mean follow-up period was 2 years and 2 months (from l2 months to 4 years). Fusion was ohtained at 29 disc spaces (96.7%) within 24 weeks (average, I 6 weeks). The anterior displacement was corrected up to the average of 65.4% (5.8mm) postoperatively and the average of 60.7% (5.2mm) correction remained at last follow-up. The intervertebral disc space was restored up to the average of 96.9% (7.5mm) postoperatively and the average of 86.0% (6.2mm) restoration remained at last follow-up. Twenty-five out of 28 patients (89.2%) showed excellent or good clinical results hy the criteria of Kim, et al6). In conclusion, the same-day procedure of successive anterior interbody fusion, decompression laminectomy and posterior pedicular instrumentation for the degenerative lumbar spondylolisthesis associated with spinal stenosis was thought to be a good method of treatment.
Constriction, Pathologic
;
Decompression
;
Follow-Up Studies
;
Hemorrhage
;
Humans
;
Intervertebral Disc
;
Laminectomy
;
Skin
;
Spinal Canal
;
Spinal Stenosis
;
Spondylolisthesis*
;
Transplants
2.A Case of Esophageal Actinomycosis in a Patient with Diabetes Mellitus.
Dong Yeong GU ; Ji Hun ROH ; Dae Gwan LIM ; Yeong Hwa JO ; Jae Hoon YU ; Jun Mo YOON ; Gi Su KIM
Korean Journal of Medicine 2012;82(5):580-584
A 47-year-old patient with diabetes mellitus was admitted with the complaints of sore throat and dysphagia. We performed an esophagogastroduodenoscopy and found esophageal ulcers. Histological examination of the esophageal biopsy revealed sulphur granules, and immunological findings ruled out viral infection. Thus, we diagnosed an isolated actinomycotic infection of the esophagus and treated the infection with oral amoxicillin. This case illustrates that actinomycotic infection of the esophagus can occur in immunocompetent patients. Therefore, when evaluating dysphagia, the probability of actinomycotic infection must be considered not only in immunocompromised patients, but in immunocompetent individualswith diabetes mellitus.
Actinomycosis
;
Amoxicillin
;
Biopsy
;
Deglutition Disorders
;
Diabetes Mellitus
;
Endoscopy, Digestive System
;
Esophagitis
;
Esophagus
;
Humans
;
Immunocompromised Host
;
Middle Aged
;
Pharyngitis
;
Ulcer
3.Correlations between Glucagon Stimulated C-peptide Levels and Microvascular Complications in Type 2 Diabetes Patients.
Hye Jin YOON ; Youn Zoo CHO ; Ji Young KIM ; Byung Joon KIM ; Keun Young PARK ; Gwan Pyo KOH ; Dae Ho LEE ; Dong Mee LIM
Diabetes & Metabolism Journal 2012;36(5):379-387
BACKGROUND: This study aimed to investigate whether stimulated C-peptide is associated with microvascular complications in type 2 diabetes mellitus (DM). METHODS: A cross-sectional study was conducted in 192 type 2 diabetic patients. Plasma basal C-peptide and stimulated C-peptide were measured before and 6 minutes after intravenous injection of 1 mg glucagon. The relationship between C-peptide and microvascular complications was statistically analyzed. RESULTS: In patients with retinopathy, basal C-peptide was 1.9+/-1.2 ng/mL, and stimulated C-peptide was 2.7+/-1.6 ng/mL; values were significantly lower compared with patients without retinopathy (P=0.031 and P=0.002, respectively). In patients with nephropathy, basal C-peptide was 1.6+/-0.9 ng/mL, and stimulated C-peptide was 2.8+/-1.6 ng/mL; values were significantly lower than those recorded in patients without nephropathy (P=0.020 and P=0.026, respectively). Stimulated C-peptide level was associated with increased prevalence of microvascular complications. Age-, DM duration-, and hemoglobin A1c-adjusted odds ratios for retinopathy in stimulated C-peptide value were 4.18 (95% confidence interval [CI], 1.40 to 12.51) and 3.35 (95% CI, 1.09 to 10.25), respectively. The multiple regression analysis between nephropathy and C-peptide showed that stimulated C-peptide was statistically correlated with nephropathy (P=0.03). CONCLUSION: In patients with type 2 diabetes, the glucagon stimulation test was a relatively simple method of short duration for stimulating C-peptide response. Stimulated C-peptide values were associated with microvascular complications to a greater extent than basal C-peptides.
C-Peptide
;
Cross-Sectional Studies
;
Diabetes Mellitus, Type 2
;
Glucagon
;
Hemoglobins
;
Humans
;
Injections, Intravenous
;
Odds Ratio
;
Plasma
;
Prevalence
4.Techniques for Reparation of Perforations of the Maxillary Sinus Membrane: Article Review
Hyoung Sup LIM ; Su Gwan KIM ; Hak Kyun KIM ; Seong Yong MOON ; Ji Su OH ; Woo Jin JEON ; Dae Woong YUN ; Seok Jin YANG
Journal of the Korean Association of Maxillofacial Plastic and Reconstructive Surgeons 2011;33(3):281-285
5.Effect of Pretreatment of Ezetimibe/Simvastatin on Arterial Healing and Endothelialization after Drug-Eluting Stent Implantation in a Porcine Coronary Restenosis Model.
Doo Sun SIM ; Myung Ho JEONG ; Dae Sung PARK ; Jung Ha KIM ; Kyung Seob LIM ; Hyun Kuk KIM ; Sung Soo KIM ; Jae Yeong CHO ; Hae Chang JEONG ; Keun Ho PARK ; Young Joon HONG ; Ju Han KIM ; Youngkeun AHN ; Jeong Gwan CHO ; Jong Chun PARK
Korean Circulation Journal 2015;45(2):110-116
BACKGROUND AND OBJECTIVES: We sought to evaluate the effect of the early use of ezetimibe/simvastatin (Vytorin(R)) on arterial healing and endothelialization after the implantation of a drug-eluting stent (DES) in a porcine model of coronary restenosis. MATERIALS AND METHODS: A total of 20 pigs (40 coronary arteries) were randomly allocated to a pretreatment or no treatment group. The pretreatment group (n=20) received oral ezetimibe/simvastatin (10/20 mg) daily for 7 days before stenting and the no pretreatment group (n=20) did not. All pigs were treated with ezetimibe/simvastatin (10/20 mg) daily after stenting for 4 weeks. Stenting was performed using a bare-metal stent (BMS, n=10) and three types of DES: biolimus A9-eluting stent (BES, n=10), zotarolimus-eluting stent (ZES, n=10), and everolimus-eluting stents (EES, n=10). Four weeks later, pigs underwent a follow-up coronary angiography and were sacrificed for histopathologic analysis. RESULTS: There were no significant differences between the pretreatment and no pretreatment groups in the internal elastic lamina area, lumen area, neointima area, stenotic area, injury score, fibrin score, and inflammation score. In both groups, the fibrin score was higher in pigs with DES than in BMS, particularly in ZES and EES. The inflammatory score was not different between DES and BMS. CONCLUSION: In a porcine model of coronary restenosis, pretreatment with ezetimibe/simvastatin before DES implantation failed to improve arterial healing and endothelialization compared to treatment after stenting.
Coronary Angiography
;
Coronary Restenosis*
;
Drug-Eluting Stents*
;
Fibrin
;
Follow-Up Studies
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors
;
Inflammation
;
Neointima
;
Stents
;
Swine
;
Ezetimibe
6.Basal C-peptide Level as a Surrogate Marker of Subclinical Atherosclerosis in Type 2 Diabetic Patients.
Sung Tae KIM ; Byung Joon KIM ; Dong Mee LIM ; In Geol SONG ; Jang Han JUNG ; Kang Woo LEE ; Keun Young PARK ; Youn Zoo CHO ; Dae Ho LEE ; Gwan Pyo KOH
Diabetes & Metabolism Journal 2011;35(1):41-49
BACKGROUND: Recent studies have revealed that C-peptide induces smooth muscle cell proliferation and causes human atherosclerotic lesions in diabetic patients. The present study was designed to examine whether the basal C-peptide levels correlate with cardiovascular risk in type 2 diabetes mellitus (T2DM) patients. METHODS: Data was obtained from 467 patients with T2DM from two institutions who were followed for four years. The medical findings of all patients were reviewed, and patients with creatinine >1.4 mg/dL, any inflammation or infection, hepatitis, or type 1 DM were excluded. The relationships between basal C-peptide and other clinical values were statistically analyzed. RESULTS: A simple correlation was found between basal C-peptide and components of metabolic syndrome (MS). Statistically basal C-peptide levels were significantly higher than the three different MS criteria used in the present study, the Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program's (NCEP's), World Health Organization (WHO), and the International Diabetes Federation (IDF) criteria (NCEP-ATP III, P=0.001; IDF, P<0.001; WHO, P=0.029). The multiple regression analysis between intima-media thickness (IMT) and clinical values showed that basal C-peptide significantly correlated with IMT (P=0.043), while the analysis between the 10-year coronary heart disease risk by the United Kingdom Prospective Diabetes Study risk engine and clinical values showed that basal C-peptide did not correlate with IMT (P=0.226). CONCLUSION: Basal C-peptide is related to cardiovascular predictors (IMT) of T2DM, suggesting that basal C-peptide does provide a further indication of cardiovascular disease.
Adult
;
Atherosclerosis
;
Biomarkers
;
C-Peptide
;
Cardiovascular Diseases
;
Carotid Arteries
;
Cholesterol
;
Coronary Disease
;
Creatinine
;
Diabetes Mellitus
;
Diabetes Mellitus, Type 2
;
Great Britain
;
Hepatitis
;
Humans
;
Inflammation
;
Myocytes, Smooth Muscle
;
World Health Organization
7.Endoscopic Mucosal Resection (EMR) as a Curative Treatment of Early Gastric Cancer.
Kyoo Wan CHOI ; Woo Ho KIM ; In Sung SONG ; Chung Yong KIM ; Hyun Chae JUNG ; Jung Hwan YOON ; Dong Ho LEE ; Kook Lae LEE ; Jun Haeng LEE ; Byeong Gwan KIM ; Jin Hyok HWANG ; Jun Oh JEONG ; Young Seok LIM ; Dae Hee LEE ; Woon Tae JEONG
Korean Journal of Gastrointestinal Endoscopy 1996;16(6):928-935
The endoscopic mucosal resection(EMR) is proposed by some Japanese investigators as a curative therapy of early gastric cancer(EGC) because of its minimal invasiveness and excellent results. To evaluate the possible role of EMR as a curative treatment modality of EGC, we retrospectively analyzed l9 casea with EGC initially treated by EMR in Seoul National University Hospital from December 1993 and January 1996. 1) The histologic diagnosis prior to EMR was adenocarcinoma in 12 cases(63%) and adenomatous polyp in 7 cases(38%), which were confirmed as adenocarcinoma after EMR. 2) The histologic curative resection was done in 7 cases(37%). Two cases of them showed recurrence of the gastric cancer and were treated by radical surgery. The other five cases have been closely observed by regular endoscopic examination without recurrence for the maximal period of 1~3 months. 3) Histoiogically inadequate resection(positive cancer cell in resection margin, submucosal cancer infiltration, or no cancer tissue in resected specimen) was done in 12 cases(73%). But two surgically resected cimens of them have no residual cancer cells, and there was no cancer cells in the follow-up biopsy of the other two patients. There 4 cases were seemed to he examples of buring effect of EMR 4) After excluding five depressed lesions greater than 1 cm is long diameter, nine lesions were curatively treated by EMR. So successful EMR rate for strictly indicated lesions wsa 64% 5) There was no signifieant complication related to the procedure. We thnnk that endoscopic mucosal resection has a potential role as a curative treatment modality in a highly selected patient with darly gastric cancer
Adenocarcinoma
;
Adenomatous Polyps
;
Asian Continental Ancestry Group
;
Biopsy
;
Diagnosis
;
Follow-Up Studies
;
Humans
;
Neoplasm, Residual
;
Recurrence
;
Research Personnel
;
Retrospective Studies
;
Seoul
;
Stomach Neoplasms*
8.New risk factors for thromboembolic complications in atrial fibrillation.
Cheon Yeong CHO ; Dae Ho JUNG ; Jum Suk KO ; Nam Sik YOON ; Sang Rok LEE ; Sang Yup LIM ; Hyung Wook PARK ; Il Suk SOHN ; Kye Hun KIM ; Young Joon HONG ; Weon KIM ; Ju Han KIM ; Young Keun AHN ; Myung Ho JEONG ; Jeong Gwan CHO ; Jong Chun PARK ; Jung Chaee KANG ; Sei Jong KIM
Korean Journal of Medicine 2006;71(4):371-380
BACKGROUND: Atrial fibrillation (AF) is the most common cause of embolic cerebral infarction. This study was performed to determine new risk factors and the mechanism underlying thromboembolism (TE) in patients with AF. METHODS: 192 patients (M:F=137:55, 61+/-11 years) with AF were randomly selected and divided into a TE (n=95) and non-TE group (n=97). Another 71 patients with AF (M:F=38:33, 55+/-14) were studied for endothelial function by measuring the level of von Willebrand factor (vWF; factor 8 related antigen), inflammation by WBC, ESR, and high sensitive CRP and coagulation system by fibrinogen, fibrinogen degradation product and fibrin d-dimer; the results were compared with 25 patients with normal sinus rhythm. RESULTS: The TE group was older than non-TE group. Hypertension (HTN), diabetes mellitus (DM), hypercholesterolemia, smoking and fine AF (AF wave amplitude <1 mm) were more frequent in the TE group. Mitral valvular disease, an ejection fraction <40% and dilated cardiomyopathy were more frequent in the TE group and the left atrial (LA) dimension was greater in the TE group. The use of anticoagulants, an angiotensin-II receptor blocker and statins were less frequently observed in the TE group. The vWF-factor 8 related antigen was higher in patients with advanced age, LV dysfunction, HTN, DM, mitral stenosis and positively correlated with age, LA dimension, LV end-diastolic and end-systolic dimension, ejection fraction, NYHA class and AF duration. The fibrinogen level was positively correlated with age, NYHA class, LA dimension and d-dimer with NYHA class. Markers for inflammation or coagulation were not significantly different in the atrial fibrillation and the sinus rhythm group. CONCLUSIONS: No use of an angiotensin-II receptor blocker or statin and fine AF may be new risk factors for TE in patients with AF. The TE risk factors are thought to increase TE by impairing endothelial function.
Anticoagulants
;
Atrial Fibrillation*
;
Cardiomyopathy, Dilated
;
Cerebral Infarction
;
Diabetes Mellitus
;
Fibrin
;
Fibrinogen
;
Humans
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors
;
Hypercholesterolemia
;
Hypertension
;
Inflammation
;
Mitral Valve Stenosis
;
Risk Factors*
;
Smoke
;
Smoking
;
Thromboembolism
;
von Willebrand Factor
9.Response: Basal C-peptide Level as a Surrogate Marker of Subclinical Atherosclerosis in Type 2 Diabetic Patients (Diabetes Metab J 2011;35:41-9).
Sung Tae KIM ; Byung Joon KIM ; Dong Mee LIM ; In Geol SONG ; Jang Han JUNG ; Kang Woo LEE ; Keun Young PARK ; Youn Zoo CHO ; Dae Ho LEE ; Gwan Pyo KOH
Diabetes & Metabolism Journal 2011;35(2):190-191
No abstract available.
Atherosclerosis
;
Biomarkers
;
C-Peptide
;
Humans
10.The Comparative Clinical Effects of Valsartan and Ramipril in Patients With Heart Failure.
Ki Hong LEE ; Myung Ho JEONG ; Young Keun AHN ; Woo Seok LEE ; Dae Ho JUNG ; Jeong Gwan CHO ; Jong Chun PARK ; Jung Chaee KANG ; Seok Kyu OH ; Nam Ho KIM ; Kyung Ho YUN ; Nam Jin YOO ; Yong MOON ; Jay Young RHEW ; Ji Hyun LIM ; Seong Hee JEON ; Ok Young PARK ; Seung Uk LEE ; Dong Goo KANG
Korean Circulation Journal 2008;38(2):101-109
BACKGROUND AND OBJECTIVES: Angiotensin II receptor blocker (ARB) has emerged as an alternative to angiotensin converting enzyme inhibitor (ACEI) for the treatment of heart failure. This study aimed at comparing the effectiveness and safety of valsartan with ramipril in patients with heart failure, and these patients were hospitalized at Chonnam National University Hospital, Wonkwang University Hospital, Gunsan Medical Center, Presbyterian Medical Center, Seonam University Hospital and Gwangju Christian Hospital. SUBJECTS AND METHODS: Between March 2005 and March 2007, 82 patients (60.5+/-12.4 years, 59 males) who complained of class II to IV dyspnea, according to the New York Heart Association (NYHA) classification, and who had low left ventricular ejection fraction (LVEF) less than 50% were randomly allocated to valsartan or ramipril. After 6 months, the clinical symptoms, vital signs, biochemical tests and echocardiography were compared between the two groups. RESULTS: The NYHA class was improved in both groups (the valsartan group: 2.31+/-0.51 vs. 1.46+/-0.58, p<0.001; the ramipril group: 2.21+/-0.55 vs. 1.61+/-0.50, p<0.001). The incidence of cough, as measured by the cough index, was significantly lower in the valsartan group than in the ramipril group (p=0.045). The LVEF was improved in both groups (the valsartan group: 36.4+/-8.5% vs. 46.9+/-12.9%, p<0.001; the ramipril group: 35.1+/-8.5% vs. 45.3+/-11.2%, p<0.001). The improvements of the left ventricular end-systolic dimension (p=0.754) and end-diastolic dimension (p=0.998) were not different between the two groups. N-terminal Pro-B-type natriuretic peptide level was improved in both groups (the valsartan group: 2619.6+/-4213.5 vs. 995.4+/-2186.0 pg/mL, p=0.012; the ramipril group: 3267.9+/-4320.0 vs. 828.1+/-1232.8 pg/mL, p=0.009), and there was no difference between the groups (p=0.877). CONCLUSION: Both valsartan and ramipril were effective treatments, with relatively low adverse events, in patients with heart failure.
Angiotensins
;
Cough
;
Dyspnea
;
Echocardiography
;
Heart
;
Heart Failure
;
Humans
;
Incidence
;
New York
;
Peptidyl-Dipeptidase A
;
Protestantism
;
Ramipril
;
Receptors, Angiotensin
;
Stroke Volume
;
Tetrazoles
;
Valine
;
Ventricular Remodeling
;
Vital Signs
;
Valsartan